Agios Pharma (AGIO) Receives a Hold from Oppenheimer


In a report released today, Mark Breidenbach from Oppenheimer maintained a Hold rating on Agios Pharma (AGIO). The company’s shares closed last Tuesday at $36.78.

According to TipRanks.com, Breidenbach is a 5-star analyst with an average return of 18.5% and a 46.0% success rate. Breidenbach covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Iovance Biotherapeutics, and Arvinas Holding Company.

Currently, the analyst consensus on Agios Pharma is a Strong Buy with an average price target of $67.71.

See today’s analyst top recommended stocks >>

Based on Agios Pharma’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $34.71 million and GAAP net loss of $98.98 million. In comparison, last year the company earned revenue of $26.02 million and had a GAAP net loss of $106 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts